Last updated on 28 December, 2020, 6:45 am PST, John Hopkins Corona Virus Dashboard and Worldometer
John Hopkins Worldometer
Recovered - 45,647,983 Recovered - 57,399,235
Cases in the U.S.
POPULATION - is 331,002,651 as of 8 November, 2020, based on Worldometer latest United Nations data.
Recovered - Recovered - 11,496,902
Cases in California
Recovered - Recovered - 840,392
12/28/2020 Cases (WHO) Deaths (WHO) Recovered (WHO)
**reporting information is limited, reduced testing and increased cases
CORONA VIRUS UPDATE
Federal officials have authorized emergency use of the COVID-19 vaccine produced by Pfizer and BioNTech in a landmark decision that promises to alter the fight against the coronavirus radically in the United States.
Documents released by the FDA, including a vaccine fact sheet and prescribing instructions, addressed several issues that came up during the advisory panel meeting Thursday. Despite some disagreement by experts on the advisory panel over the adequacy of evidence to support use of the vaccine in people as young as 16, the vaccine was authorized for use in people 16 and older.
The vaccine shouldn't be given to people with a history of severe allergic reactions to any of the ingredients in the vaccine, the instructions say. Medical treatment for serious allergic reactions that occur immediately after injection must be available.
It didn’t have to happen!!! How did we get here???? Remember………
The United States was alerted regarding the “virus” identified in China in December 2019, with the first U.S. case identified in January, 2020, in the Washington state area. Instead of utilizing the pandemic playbook left by the Obama administration, Trump declared the virus a hoax, a democratic attempt to discredit his presidency, etc. Where would we be if the document had been utilized!
Ronald Klain, the White House Ebola response coordinator, October 2014 to February 2015, out a link to a titled “Playbook for Early Response to High-Consequence Emerging Infectious Disease Threats and Biological Incidents.” The document, a 69-page National Security Council guidebook developed in 2016, with the goal of assisting leaders “in coordinating a complex U.S. Government response to a high-consequence emerging disease threat anywhere in the world.” It outlined questions to ask, who should be asked to get the answers and what key decisions should be made.
The playbook lists types of infectious disease threats that could emerge. “Novel coronaviruses” were among pathogens flagged as having potential to cause heightened concern. Lurie said that “there were tabletop exercises, which included planning for a pandemic-like situation, during the the Obama and Trump administrations. The Trump administration also conducted an exercise known as “,” in 2019! So what happened that the Trump administration ignored the information and advice??? Lets review the first trimester of 2020.
CORONA VIRUS / COVID 19 TIMELINE
symptoms of unknown etiology.”
cases were reported worldwide, including in 18 countries beyond China.
people, including passengers and crew, onboard.
cut funding for WHO and global health funding.
and remain beyond this season.
been silently spreading in Washington State. Analysis traced the outbreak origin to
a traveler designated WA1, after his arrival from China on 15 January.
level of inaction made the assessment that COVID-19 be characterized a pandemic.
California and Washington recording the most confirmed cases. The national death
toll rose to 61.
- A vote to advance a massive coronavirus stimulus bill failed in the Senate.
- United States reaches 50,000 coronavirus cases.
Pandemic with 54,810 recorded coronavirus cases, including 781 deaths.
cases double every three days.
in the world.
We were warned, but chose to ignore the severity!
We are preparing to enter the influenza season and there has been documentation of patients exhibiting both influenza and covid like symptoms. The United States reported over 4 million cases of COVID-19 during the month of November alone.
As of today, December 1st, there have been 13,546,787 cases, 268,103 deaths and only 5,145,319 that have recovered from the pandemic. The United States, the most developed country, has 21 percent of the covid cases!
Source: Worldometer -
The U.S. recorded its highest daily death toll since May on Tuesday, November 24th and experts warned that good vaccine news doesn't mean Americans should let down their guard down over the holidays. Several state restrictions go into effect Wednesday just hours before the Thanksgiving holiday, including a ban on alcohol sales at restaurants and bars in Pennsylvania, starting at 5 p.m. Wednesday until 8 a.m. Thursday in an effort to prevent social gatherings.
The New York Times reported a milestone of more than 170,000 people testing positive for the coronavirus on an average day, just after the country celebrated Thanksgiving and thousands participating in Black Friday shopping.
Politicians across the country asked “people to refrain from congregating during the holiday season” as the number of coronavirus cases worldwide hit 60 million last week. Several politicians drew scrutiny for making those requests then simultaneously disregarding them, including the mayor of Denver, who told residents to avoid travel and then took a flight to Texas to see family.
Wyoming Gov. Mark Gordon tested positive for COVID-19, with minor symptoms and plans to continue working remotely. The governor's office was closed Tuesday for a deep cleaning after another office employee tested positive for the virus. Two weeks ago, Gordon said Wyoming residents “needed to be more responsible about preventing the spread of COVID-19,” complaining some people were being "knuckleheads."
Denver Mayor Michael Hancock apologized for flying to visit family members in Mississippi while tweeting advice to city residents, “asking them to avoid traveling.” Hancock said his family canceled plans for a large gathering and instead he visited his wife and daughter, staying in Mississippi. Hancock said he believed traveling alone was a lower risk than having both of them return home for the holiday. One consistency with this administration: misinformation, disinformation and “talking out their neck!” What is that mantra….”do as I say, not as I do!!!”
COVID-19 infections in children less severe. While children are susceptible to COVID-19 and cases are rising with cooler temperatures driving us indoors, a relatively low percentage of infants, toddlers, and young children have been infected. The majority of children infected had, mild to moderate symptoms, according to the American Academy of Pediatrics (AAP). Reports of rare clusters of COVID-19-exposed children and adolescents admitted to intensive care units with acute multisystem inflammatory conditions have researchers working overtime to collect more data and fully understand causality.
There are cases of babies and children being infected, including a report of an infected newborn born to a mother who was sick with COVID-19. Health officials and scientists are still learning about the disease, so it's still possible they'll discover evidence of greater effects on children. As of November 12, 2020, the AAP reported:
An AAP study of over 2,000 pediatric patients showed nearly 90% of children were asymptomatic, mild or moderate. The study also showed the percentage of infants with serious symptoms to be higher than that of older children. The fact remains, those most at risk of serious infection from the coronavirus appear to be the middle-aged and elderly.
Vaccine Update - Coronavirus Vaccine Tracker
By Carl Zimmer, Jonathan Corum and Sui-Lee Wee, Updated November 27, 2020
PHASE 1 PHASE 2 PHASE 3 LIMITED APPROVED
38 17 13 6 0
Vaccines Vaccines Vaccines Vaccines Vaccines
testing safety in expanded in large scale approved for early approved
and dosage safety trials efficacy tests or limited use full use
The Vaccine Testing Process
Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective coronavirus vaccine by next year. Researchers are testing 55 vaccines in clinical trials on humans, and at least 87 preclinical vaccines are under active investigation in animals. The first vaccine safety trials in humans started in March and now 13 have reached the final stages of testing.
Here is the status of companies whose vaccines have reached Phase 2, Phase 3 and Combined trials:
The United States government bankrolled Moderna’s efforts, providing nearly $1 billion in support, then an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective. Nov. 25, the company reached an agreement with the European Commission to supply up to 160 million doses and made similar deals with Canada, Japan, and Qatar.
Johnson & Johnson began Phase 1 - 2 trials in July and a Phase 3 trial with 60,000 participants in September. Unlike other Phase 3 trials, Johnson & Johnson administered just a single dose instead of two. In March they received $456 million from the United States government to support the move towards production. The vaccine has provided protection in experiments on monkeys.
In August, the federal
government agreed to pay $1 billion for 100 million doses if the vaccine is approved.
The European Union reached a similar deal on Oct. 8 for 200 million
doses. The company is aiming for production of at least a billion doses in 2021.
Oct. 12, Johnson & Johnson announced the trial was put on pause to investigate an adverse reaction in a volunteer. The trial resumed eleven days later and despite the delay, the company expects results by the end of the year. Nov. 16, Johnson & Johnson announced they were launching a second Phase 3 trial to observe the effects of two doses of their vaccine, instead of just one.
After promising results in monkeys and humans, Novavax launched a Phase 2 trial in South Africa in August. The blinded, placebo-controlled trial on 2,900 people will measure the safety of the vaccine and its efficacy. In September, Novavax launched a Phase 3 trial of 15,000 volunteers in the United Kingdom and could possibly deliver results by the start of 2021. A larger Phase 3 trial is in development to launch in the United States by the end of November.
Novavax reached an agreement with the Serum Institute of India which would enable them to produce 2 billion doses a year. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021.
Phase 2 - Phase 3, Combined Phases
One version, BNT162b2, produced significantly fewer side effects, such as fevers and fatigue and was chosen to move into Phase 2 - 3 trials July 27, with 30,000 volunteers in the United States, Argentina, Brazil and Germany. In September the trial was expanded to 43,000, followed by permission to start testing on children as young as 12. Pfizer and BioNTech concluded that the vaccine is 95% effective, with 94% effectiveness among people over 65.
Preparation of the vaccine is based on mRNA, which falls apart unless kept in a deep freeze or chilled to minus 70 degrees Celsius (minus 94 degrees Fahrenheit) until injected! In addition, it requires two doses which will add an extra layer of complexity to the vaccine’s distribution, dividing in half the available dosages.
President Trump touted their progress, hinting a vaccine would be available before the election then later Dr. Bourla announced volunteers in the trial had yet to experience enough cases of Covid-19 to determine if the vaccines work. July, the Trump administration awarded a $1.9 billion contract for 100 million doses to be delivered by December and the option to acquire 500 million additional doses. Japan made a deal for 120 million doses and the European Union arranged to purchase 200 million doses. If the vaccine is authorized, Pfizer and BioNTech expect to manufacture over 1.3 billion doses of their vaccine worldwide by the end of 2021.
Oxford researchers began by
testing the vaccine, ChAdOx1, on monkeys, finding it protected the animals from the disease. In a Phase 1 - 2 trial, the developers did not
detect any severe side effects, but noticed it raised antibodies against the coronavirus as well as other immune defenses. The vaccine began Phase 2 - 3 trials in the
United Kingdom and India, known as Covishield, and launched Phase 3 trials in Brazil, South Africa and the United States.
Sept. 6, AstraZeneca halted global trials of the vaccine to investigate one volunteer, who developed a form of inflammation, transverse myelitis. Trials resumed within a week, in all countries except the United States. Oct. 23, the F.D.A. authorized the restart of the U.S. trial.
Nov. 19, researchers published the first findings from the Phase 2 - 3 trials in the United Kingdom, looking specifically at how people at different ages responded to the vaccine and didn’t observe any serious side effects at any age.
Volunteers got two doses, but some cases the first dose was only half strength. An initial half-strength dose led to 90% efficacy, while two standard-dose shots led only to 62%? What??? Excuse me??? Researchers speculated the lower first dose did a better job mimicking the experience of an infection, while promoting a stronger immune response. It became clear the low dose version was the result of a mistake in how the vaccines were measured out and the low dose was only tried on volunteers under 55, raising more questions about how strong the preliminary results were.
The United States awarded the project $1.2 billion in support for 300 million doses. August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.
CureVac has collaborated with Elon Musk’s company Tesla on creating mRNA “micro-factories,” which could potentially be deployed around the world to make billions of doses of the vaccine. November, CureVac negotiated a deal to provide the European Union up to 225 million doses of vaccine, projecting they could manufacture up to 300 million doses in 2021 and 600 million doses the following year. Nov. 12, the company announced its vaccine could be kept refrigerated at 41 degrees.
Is Herd Immunity Still A Thought?? A vaccine for the COVID-19 virus would be ideal, creating immunity without causing illness or resulting complications. This concept has been successful in controlling deadly contagious diseases such as smallpox, polio, diphtheria, rubella and many others.
But herd immunity through vaccination sometimes has drawbacks. Vaccination protections wane over time, requiring a dreaded re-vaccination, which some people will not complete. Others may object to vaccines for religious reasons, fears about the possible risks or skepticism about the benefits. If the proportion of vaccinated people in a community falls below the herd immunity threshold, exposure to contagions could result in a disease quickly spreading, hence the resurgence of Measles in parts of the world with relatively low vaccination rates - including the United States! Opposition to vaccinations can pose a real challenge to herd immunity.
Even if infection with the COVID-19 virus creates long-lasting immunity, a large number of the population would have to become infected to reach the herd immunity threshold. Experts estimate that 70%, 200 million people or more of the 331 million, of the U.S. population would have to recover from COVID-19 to halt the epidemic - 200 million of 331 million! Seriously!! That astounding number of the sick with COVID-19 all at once would overwhelm the health care system - and they are already exhausted and being depleted by infection!
WHAT CAN WE DO UNTIL THE VACCINES ARE AVAILABLE?? There's no vaccine against the coronavirus, yet! However, we repeat, you can take basic precautions to reduce your family's risk of getting this and other illnesses by:
Stay safe. Mask. Social distance. Frequent hand washing. Avoid crowds.
ALWAYS CONSULT YOUR PERSONAL HEALTH CARE PROFESSIONAL
1756 N. Riverside Ave
Rialto, CA 92376
Phone: 909 879-1059
Fax : 909 879-1043
Monday 10 am - 5:00 pm Tuesday 10 am - 5:00 pm
Wednesday 10 am - 5:00 pm
Thursday 10 am - 5:00 pm
Friday 10 am - 5:00 pm
Saturday 10 am - 3 pm
HOLIDAY HOURS MAY VARY
10:30 am - 3 pm
Phone orders are encouraged. Large orders prior to 10:30 am
Deliveries not available during covid restrictions.
Stop in to check out all the items currently discounted for your personal resolutions.